Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript Summary
Abbott Laboratories (ABT) Q3 2023 Earnings Call Summary
Here are the specific viewpoints from the earnings call:
Bullish Points:
1. Organic sales growth on the base business increased double digits for the third consecutive quarter.
2. Double-digit growth in all four major businesses.
3. Strong position in attractive growth markets.
4. Additional investments made across the company during the pandemic.
5. Positive growth outlook for the businesses.
6. Momentum building across the portfolio.
7. High confidence level in delivering high single-digit organic revenue growth and solid margin expansion in 2024.
8. Top-line growth expected to accelerate next year.
9. Street models double-digit EPS on the base business.
10. Gross margin expansion expected.
Bearish Points:
1. Lower gross margins on COVID tests due to lower volumes and price.
2. Higher inventory obsolescence.
3. Unfavorable impact of foreign exchange on sales.
4. Potential impact of GLP-1 drugs on future medtech market growth.
5. Concerns over coverage and cost of GLP-1 drugs.
6. Side effects of GLP-1 drugs, such as muscle mass loss.
7. Competition in electrophysiology and MitraClip.
8. Nutrition not yet fully recovered to pre-recall market share.
9. China VBP for diagnostics impacting 20% of the market.
10. Gross margin challenges due to commodity costs and supply chain disruptions.
For more information about Abbott Laboratories(ABT)'s earnings call, you can read the relevant news: Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
